Mitochondrial DNA mutations in differentiated thyroid cancer with respect to the age factor

World Journal of Surgery

Volumn 31, Issue 1, 2007, Pages 51-59

  Witte, Jürgen ^a   Lehmann, Steffen ^a   Wulfert, Michael ^a   Yang, Quin ^a   Röher, Hans D ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; MITOCHONDRIAL DNA;

ADULT; AGING; ANALYTICAL EQUIPMENT; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CHROMATOGRAPHY; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA EXTRACTION; DNA POLYMORPHISM; DNA SEQUENCE; FEMALE; FOLLICULAR CARCINOMA; FOLLOW UP; FREEZING; GENDER; GENE MUTATION; GENETIC DATABASE; GENOMICS; HETEROPLASMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; METASTASIS; PAPILLARY CARCINOMA; POLYMERASE CHAIN REACTION; PROGNOSIS; SAMPLE; STATISTICAL ANALYSIS; THYROID CANCER; THYROID GLAND; TISSUE FIXATION; TUMOR VOLUME; UNIVARIATE ANALYSIS; VALIDATION PROCESS;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; ADOLESCENT; ADULT; AGE FACTORS; CELL DIFFERENTIATION; DNA, MITOCHONDRIAL; FEMALE; HUMANS; MALE; POLYMERASE CHAIN REACTION; PROGNOSIS; THYROID NEOPLASMS;

EID: 33846144801     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-005-0447-5     Document Type: Article

References (72)

1. Warburg O. On the origin of cancer cells. Science 1956;123:309-314.
2. Stefaneanu L, Tasca C. An electron-microscopic study of human thyroid cancer. Endocrinologie 1979;17:233-239.
3. Katoh R, Harach HR, Williams ED. Solitary, multiple, and familial oxyphil tumours of the thyroid gland. J Pathol 1998;186:292-299.
4. Yeh JJ, Lunetta KL, van Orsouw NJ, et al. Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours. Oncogene 2000;19:2060-2066.
5. Anderson S, Bankier AT, Barrell BG, et al. Sequence and organisation of the human mitochondrial genome. Nature 1981;290:457-465.
6. DiMauro S, Bonilla E, Zeviani M, et al. Mitochondrial myopathies. Ann Neurol 1985;17:521-538.
7. Holt IJ, Harding AE, Morgan-Hughes JA. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nuture 1988;331:717-719.
8. Wallace DC, Singh G, Lott MT, et al. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 1988;242:1427-1430.
9. Zeviani M, Moraes CT, DiMauro S, et al. Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology 1988;38:1339-1346.
10. Pennisi E. Do mitochondrial mutations dim the fire of life? Science 1999;286:664.
11. Corral-Debrinski M, Horton T, Lott MT, et al. Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat Genet 1992;2:324-329.
12. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma: a study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer 1979;15:1033-1041.
13. Akslen LA, Haldorsen T, Thoresen SO, et al. Incidence of thyroid cancer in Norway 1970-1985. APMIS 1990;98:549-558.
14. Shaha AR, Shah JP, Loree TR. Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg 1997;174:474-476.
15. Loh KC, Greenspan FS, Gee L, et al. Pathological tumour-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997;82:3553-3562.
16. Cunningham MP, Duda RB, Recant W, et al. Survival discriminants for differentiated thyroid cancer. Am J Surg 1990;160:344-347.
17. Schelfout LJDM, Creutzberg CL, Hamming JF, et al. Multivariate analysis of survival in differentiated thyroid cancer: the prognostic significance of the age factor. Eur J Cancer Clin Oncol 1998;24:331-337.
18. Sanders LE, Siverman M. Follicular and Hürthle cell carcinoma: predicting outcome and directing therapy. Surgery 1998;:967-974.
19. van Heerden JA, Hay ID, Goellner JR, et al. Follicular thyroid carcinoma with capsular invasion alone: A nonthreatening malignancy. Surgery 1992;112:1130-1138.
20. DeGroot LJ, Kaplan EL, Shukla MS, et al. Morbidity and mortality in follicular thyroid cancer. J Clin Endocrinol Metab 1995;80:2946-2953.
21. Tenvall J, Björklund A, Möller T, et al. Is the EORTC progonostic index of thyroid cancer valid in differentiated thyroid carcinoma? Cancer 1986;57:1405-1414.
22. Böttger T, Klupp J, Sorger K, et al. Prognostisch relevante Faktoren beim follikulären Schiddrüsenkarziom. Langenbecks Arch Chir 1990;375:266-271.
23. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281:1309-1312.
24. Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today 1997;18:45-51.
25. Korsmeyer SL, Yin XM, Oltvai ZN, et al. Reactive oxygen species and the regulation of cell death by the Bcl-2 gene family. Biochim Biophys Acta 1995;1271:63-66.
26. Rudin CM, Thompson CB. Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annu Rev Med 1997;48:267-281.
27. Wang HG, Reed JC. Mechanisms of Bcl-2protein function. Histol Histopathol 1998;13:512-530.
28. Cavalli LR, Liang BC. Mutagenesis, tomourigenicity, and apoptosis:are the mitochondria involved? Mutat Res 1998;398:19-26.
29. Chen LB. Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 1988;4:155-181.
30. Augenlicht LH, Heerdt BG. Modulation of gene expression as a biomarker in colon. J Cell Biochem Suppl 1992; 16:151-157.
31. Habano W, Nakamura S, Sugai T. Microsatellite instability in the mitochondrial DNA of colorectal carcinomas:evidence for mismatch repair systems in mitochondrial genome. Oncogene 1998;17:1931-1937.
32. Habano W, Sugai T, Yoshida T, et al. Mitochondrial gene mutation, but not large -scale deletion, is a feature of colorectal carcinoma with mitochondrial microsatellite instability. Int J Cancer 1992;83:625-629.
33. Polyak K, Li Y, Zhu H, et al. Somatic mutation of the mitochondrial genome in human colorectal tumours. Nat Genet 1998;20:291-293.
34. Tamura G, Nishizuka S, Maesawa C, et al. Mutations in mitochondrial control region DNA in gastric tumours of Japanese patients. Eur J Cancer 1999;35:316-319.
35. Habano W, Sugai T, Nakamura SI, et al. Microsatellite instability and mutation of mitochondrial and nuclear DNA in gastric carcinoma. Gastroenterology 2000;118:835-841.
36. Maximo V, Soares P, Seruca R, et al. Comments on mutation in mitochondrial control region DNA in gastric tumours of Japanese patients. Eur J Cancer 1999;35:1407-1408.
37. Maximo V, Soares P, Seruca R, et al. Microsatellite instability, mitochondrial DNA large deletions, and mitochondrial DNA mutations gastric carcinoma. Genes Chromosom Cancer 2001;32:136-143.
38. Richard SM, Bailliet G, Paez GL, et al. Nuclear and mitochondrial genome instability in human breast cancer. Cancer Res 2000;60:4231-4237.
39. Tallini G, Ladanyi M, Rosai J, et al. Analysis of nuclear and mitochondrial DNA alteration in thyroid and renal oncocytic tumours. Cytogenet Cell Genet 1994;66:253-259.
40. Muller-Höcker J, Jacob U, Seibel P. Hashimoto thyroiditis is associated with defects of cytochrome-c oxidase in oxyphil Askanazy cells and with the common deletion (4997) of mitochondrial DNA. Ultrastruct Pathol 1998;22:91-100.
41. Maximo V, Soares P, Rocha AS, et al. The common deletion of mitochondrial DNA is found in goitres and thyroid tumours with and without oxyphil cell change. Ultrastruct Pathol 1998;22:271-273.
42. Maximo V, Sobrinho-Simoes M. Mitochondrial DNA 'common' deletion in Hurthle cell lesions of the thyroid. J Pathol 2000;92:561-562.
43. Ebner D, Rodel G, Pavenstaedt I, et al. Functional and molecular analysis of mitochondria in thyroid oncocytoma. Virchows Arch 1991;63:908-911.
44. Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumours:a commentary on the second edition. Cancer 1989;63:908-911.
45. Greer CE, Peterson SL, Kiviat NB, et al. PCR amplification from paraffin-embedded tissues. Am J Pathol 1991;95:117-124.
46. Linz U, Degenhardt H. Die Polymerasekettenreaktion. Ein Überblick. Naturwissenschaften 1990;77:515-530.
47. Wickham CL, Boyce M, Joyner MV, et al. Amplification of PCR products in excess of 600 base pairs using DNA extracted from decalcified, paraffin wax embedded bone marrow trephine biopsies. J Clin Pathol 2000;53:19-23.
48. Taylor P, Munson K, Gjerde D. Detection of mutations and polymorphisms on the WAVE DNA fragment analysis system. Application note no. 101. Crewe, UK, Transgenomic, 1998.
49. Xiao W, Oeffner PJ. Denaturing high-performance liquid chromatography:a review. Hum Mutat 2001;17:439-474.
50. Moraes CT, Shanshe S, Tritschler H-J, et al. Mitochondrial DNA depletion with variable tissue expression:a novel genectic abnormality in mitochondrial diseases. Am J Hum Genet 1991;48:4992-4501.
51. Naviaux RK. Mitochondrial DNA depletion syndromes. In: Nyhan WL, Ozand P, (editors), Atlas of Metabolic Disease. London, Chapman & Hall, 1999.
52. Tell G, Crivellato E, Pines A, et al. Mitochondrial localisation of APE/Ref-1 in thyroid cells. Mutat Res 2001;485:143-152.
53. Johnson D, Tallini G, Silna D, et al. Mitochondrial mutational analysis of oncocytic neoplasms [abstract]. Am Pathol 1996;149:1786.
54. Wallace DC. Mitochondrial genes and disease. Hosp Pract 1986;21:77-87,90-92.
55. Maximo V, Soares P, Lima J, et al. Mitochondrial DNA somatic mutations (point mutations and large deletions ) and mitochondrial DNA variants in human thyroid pathology: study with emphasis on Hürthle cell tumours. Am J Pathol 2002;160:1857-1865.
56. McConahey WM, Hay ID, Woolner LB, et al. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: intial manifestation, pathologic findings, theraphy, and outcome. Mayo Clin Proc 1986;61:978-996.
57. Cady B, Sedwick CE, Weissner WA, et al. Risk factors analysis in differentiated thyroid. Cancer 1986;43:810-820.
58. Mazzaferri EL. Papillary thyroid carcinoma; factors influencing prognosis and current theraphy. Semin Oncol 1987;14:315-322.
59. Tubiana M, Schlumberger M, Rougier P, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985;55:794-804.
60. Halnan KE. Age and sex in thyroid cancer. Cancer 1966;19:1534.
61. Cady B. Changing clinical, pathologic, therapeutic and survial in differentiated thyroid carcinoma. Ann Surg 1976; 184:541-552.
62. Russell MA, Gilbert EF, Jaeschke WF. Prognostic features of thyroid cancer. Cancer 1975;36:553-559.
63. Crile G Jr. Relationship of age to natural history and prognosis in thyroid cancer. 1953;138:33-38.
64. De Groot LJ, Kaplan EL, McCormick M, et al. Natural history, treatment and course of papillary thyroid cancer. J Clin Endrocrinol Metab 1990;71:414-424.
65. Farahati J, Mörtl M, Reiners C. Die Bedeutung des Lymphknotenstatus beim papillären und follikulären Schildddrüsenkarzinom für den Nuklearmediziner. Zentralbl Chir 2000;125:830-834.
66. Seller CA, Schäfer M, Büchler MW. Pro und Contra Lymphadenektomie beim papillären und follikulären Schilddrü senkarzinom. Zentralbl Chir 2000;125:830-834.
67. Witte J, Goretzki PE, Dieken J, et al. Importance of lymph node metastases in follieular thyroid cancer. World J Surg 2002;26:1017-1022.
68. Michikawa Y, Mazzucchelli F, Bresolin N, et al. Agingdepending large accumulation of point mutations in fee human mtDNA control region for replication. Science 1999;686:774-779.
69. Maximo V, Sobrmho-Simoes M. Hürthle cell tumours of the thyroid: a review with emphasis on mitochondrial abnormalities with clinical relevance. Virchows Arch 1995;437:107-115.
70. Melov S, Shoffner JM, Kaufman DC, et al. Marked increase in the number and variety of mitochondrial DNA rearrangements in aging human skeletal muscle. Nucleic Acids Res 2000;437:41226-4126.
71. Croteau DL, Bohr VA. Repair of oxidative damage to nuclear and mitochondrial DNA in mammalian cells. Biol Chem 1997;72:25409-25412.
72. Khrapko K, Coller HA, Andre PC, et al. Mitochondrial inutational spectra in human calls and tissues. Proc Natl Acad Sci USA 1997;4:13798-l3803.